-
公开(公告)号：US20160129110A1
公开(公告)日：2016-05-12
申请号：US14802247
申请日：2015-07-17
发明人： Robert Francis GARRY , Luis Manuel BRANCO , Bruce Alan BUNNELL , Russell B. WILSON , Samuel E. HOPKINS
CPC分类号： A61K39/42 , A61K35/28 , C07K16/10 , C07K2317/76 , C12N5/0667 , C12N2510/00 , G01N33/6854 , Y02A50/387 , Y02A50/389 , Y02A50/393 , Y02A50/395 , Y02A50/402 , Y02A50/406 , Y02A50/409 , Y02A50/411 , Y02A50/421 , Y02A50/423 , Y02A50/463 , Y02A50/465 , Y02A50/469 , Y02A50/471 , Y02A50/475 , Y02A50/478 , Y02A50/48 , Y02A50/481 , Y02A50/491
摘要： Immunoprotective primary mesenchymal stems cells (IP-MSC) which episomally express multiple immunoreactive polypeptides that specifically target a pathogen (e.g., an infectious species of virus, bacterium, or parasite) or toxin are described herein. The IP-MSC express two or more (e.g., 2 to about 100) immunoreactive polypeptides (e.g., full antibodies, single-chain antibodies (ScFV), Fab or F(ab)2 antibody fragments, diabodies, tribodies, and the like), and optionally one or more other immunomodulating polypeptides, e.g., a cytokine such as an interleukin (e.g., IL-2, IL-4, IL-6, IL-7, IL-9, and IL-12), an interferon (e.g., IFNα, IFNβ, or IFNω), and the like, which can enhance the effectiveness of the immunoreactive polypeptides.
摘要翻译： 本文描述了附加表达特异性靶向病原体（例如病毒，细菌或寄生虫）或毒素的感染物种的多种免疫反应性多肽的免疫保护性原代间充质干细胞（IP-MSC）。 IP-MSC表达两种或更多种（例如，2至约100）免疫反应性多肽（例如，全抗体，单链抗体（ScFV），Fab或F（ab）2抗体片段，双抗体，抗体等） ，和任选的一种或多种其它免疫调节多肽，例如细胞因子如白细胞介素（例如IL-2，IL-4，IL-6，IL-7，IL-9和IL-12），干扰素 例如IFNα，IFN和bgr，或IFNω）等，其可增强免疫反应性多肽的有效性。
-
公开(公告)号：US09056900B2
公开(公告)日：2015-06-16
申请号：US13962524
申请日：2013-08-08
发明人： Robert F. Garry , Russell B. Wilson
IPC分类号： A61K38/04 , A61K38/16 , C07K7/08 , C07K14/005 , C07K7/00 , C12Q1/18 , G01N33/569 , C07K7/06 , A61K38/00
CPC分类号： C07K14/005 , A61K38/00 , A61K38/04 , A61K38/162 , C07K7/00 , C07K7/06 , C07K7/08 , C12N7/00 , C12N2760/10022 , C12N2760/14122 , C12N2760/18422 , C12N2760/18433 , C12N2770/20022 , C12Q1/18 , G01N33/56988
摘要： The present invention provides compositions and methods for treating a coronavirus infection. A method embodiment comprises administering a polypeptide (preferably in a biocompatible pharmaceutical carrier) to a subject suffering from a coronavirus infection. The polypeptide comprises or consists of at least a portion of the fusion initiation region (FIR) of a coronavirus fusion protein. In some embodiments, the polypeptide comprises or consists of a sequence selected from SEQ ID NO: 2, 22, 23, 24, and 25 or an 8 to 40 contiguous amino acid residue portion thereof.
摘要翻译： 本发明提供了用于治疗冠状病毒感染的组合物和方法。 方法实施方案包括向患有冠状病毒感染的受试者施用多肽（优选在生物相容性药物载体中）。 多肽包含冠状病毒融合蛋白的融合起始区（FIR）的至少一部分或由其构成。 在一些实施方案中，多肽包含选自SEQ ID NO：2,22,23,24和25的序列或其8至40个连续氨基酸残基部分。
-
93.发明申请公开(公告)号：US20150119318A1
公开(公告)日：2015-04-30
申请号：US14327287
申请日：2014-07-09
IPC分类号： C07K14/005
CPC分类号： C07K14/005 , A61K38/00 , A61K39/00 , A61K39/12 , A61K39/245 , C07K14/045 , C12N2710/16122 , C12N2710/16133
摘要： The present invention provides an isolated peptide having an amino acid residue sequence that comprises at least one human cytomegalovirus glycoprotein B (HCMV-gB) sequence segment, each HCMV-gB sequence segment consisting of at least 8 and not more than 60 consecutive amino acid residues from residues 146 to 315, residues 476 to 494 of SEQ ID NO: 1, or from a sequence variant of residues 146 to 315 or 476 to 494 of SEQ ID NO: 1 that has at least 70% sequence identity thereto. The peptides of the invention are useful for treating, preventing, or inhibiting a herpesvirus (e.g., Herpes Simplex Virus-1, Human Cytomegalovirus, and the like) infection in a subject.
摘要翻译： 本发明提供了具有包含至少一种人巨细胞病毒糖蛋白B（HCMV-gB）序列片段的氨基酸残基序列的分离肽，每个HCMV-gB序列片段由至少8个且不超过60个连续氨基酸残基组成 来自SEQ ID NO：1的残基146至315，SEQ ID NO：1的残基476至494或与SEQ ID NO：1具有至少70％序列同一性的SEQ ID NO：1的残基146至315或476至494的序列变体。 本发明的肽可用于治疗，预防或抑制受试者中疱疹病毒（例如，单纯疱疹病毒-1，人巨细胞病毒等）感染。
-
公开(公告)号：US20150087693A1
公开(公告)日：2015-03-26
申请号：US14398330
申请日：2013-05-02
申请人： The Board of Regents of the University of Texas System , The Administrators of the Tulane Educational Fund
发明人： Shusheng Wang , Eric Olson , Qinbo Zhou
IPC分类号： C12N15/113 , A61K45/06 , A61K31/713 , A61K31/7105
CPC分类号： C12N15/113 , A61K31/7105 , A61K31/713 , A61K45/06 , C12N2310/113 , C12N2310/14 , C12N2310/141 , C12N2310/3231
摘要： The present invention relates to the involvement of miR function in the development of age-related macular degeneration (AMD). It is shown that miR-23, miR-24 and/or miR-27 are involved in pathologic neovascularization in AMD, and that agonism (miR-24) and inhibition (miR23/27) of the function of these molecules blocks events contributing to development and progression of disease.
摘要翻译： 本发明涉及miR功能参与年龄相关性黄斑变性（AMD）的发展。 显示miR-23，miR-24和/或miR-27参与AMD的病理性新生血管形成，并且这些分子的功能的激动（miR-24）和抑制（miR23 / 27）阻止事件有助于 疾病的发展和进展。
-
公开(公告)号：US20150056710A1
公开(公告)日：2015-02-26
申请号：US14464658
申请日：2014-08-20
CPC分类号： G01N15/0211 , G01N21/51 , G01N21/53 , G01N33/6803 , G01N2021/4711 , G01N2021/4719 , G01N2021/4726 , G01N2021/4792 , G01N2201/0612 , G01N2201/08 , G01N2201/1224
摘要： Simultaneous Multiple Sample Light Scattering systems and methods can be used to for polymer stability testing and for applying stressors to polymer or colloid solutions including heat stress, ultrasound, freeze/thaw cycles, shear stress and exposure to different substances and surfaces. among others, that create a polymer stress response used to characterize the polymer solution and stability.
摘要翻译： 同时多重样品光散射系统和方法可用于聚合物稳定性测试和将应激物施加到聚合物或胶体溶液，包括热应力，超声波，冻融循环，剪切应力和暴露于不同物质和表面。 其中，产生用于表征聚合物溶液和稳定性的聚合物应力响应。
-
公开(公告)号：US20150000358A1
公开(公告)日：2015-01-01
申请号：US14215952
申请日：2014-03-17
CPC分类号： C05G3/00 , C02F11/004 , C02F11/06 , C02F11/14 , C02F2101/305 , C02F2303/02 , C02F2303/04 , C02F2305/00 , C02F2305/02 , C05D9/02 , C05F7/00 , Y02A40/213
摘要： In order to render sewage sludge suitable for beneficial purposes, it must be disinfected and stabilized. EDC deactivation is rapidly becoming a desirable result of any sludge or biosolids treatment process. Disclosed herein is a process of treating sewage sludge so as to stabilize the sludge that involves the presence of an iron-containing compound during dewatering of the sludge. Process embodiments described also achieve biosolid samples that have reduced EDC activity, Other embodiments disclosed involve use of a combination of iron salts ferrate and ferric chloride that are added to wastewater sludge in the dewatering step before heat drying. The biosolids resulting from sludge treated with aniron-containing compound are able to resist putrefaction for more than two to three weeks.
摘要翻译： 为了使污水污泥适合用于有益目的，必须进行消毒和稳定。 EDC失活正迅速成为任何污泥或生物固体处理工艺的理想结果。 本文公开了一种处理污泥的方法，以便在污泥脱水期间稳定涉及含铁化合物的存在的污泥。 所描述的方法实施方案还实现了具有降低的EDC活性的生物固体样品。所公开的其它实施方案涉及在加热干燥之前在脱水步骤中加入到废水污泥中的铁盐和铁氯化物的组合的使用。 由含铁化合物处理的污泥产生的生物固体能够抵抗腐败超过两至三周。
-
公开(公告)号：US08802106B2
公开(公告)日：2014-08-12
申请号：US13505099
申请日：2010-10-29
IPC分类号： C07K14/045 , A61P31/22 , A61K39/245 , C07K14/005 , A61K39/00 , A61K38/00
CPC分类号： C07K14/005 , A61K38/00 , A61K39/00 , A61K39/12 , A61K39/245 , C07K14/045 , C12N2710/16122 , C12N2710/16133
摘要： The present invention provides an isolated peptide having an amino acid residue sequence that comprises at least one human cytomegalovirus glycoprotein B (HCMV-gB) sequence segment, each HCMV-gB sequence segment consisting of at least 8 and not more than 60 consecutive amino acid residues from residues 146 to 315, residues 476 to 494 of SEQ ID NO: 1, or from a sequence variant of residues 146 to 315 or 476 to 494 of SEQ ID NO: 1 that has at least 70% sequence identity thereto. The peptides of the invention are useful for treating, preventing, or inhibiting a herpesvirus (e.g., Herpes Simplex Virus-1, Human Cytomegalovirus, and the like) infection in a subject.
摘要翻译： 本发明提供了具有包含至少一种人巨细胞病毒糖蛋白B（HCMV-gB）序列片段的氨基酸残基序列的分离肽，每个HCMV-gB序列片段由至少8个且不超过60个连续氨基酸残基组成 来自SEQ ID NO：1的残基146至315，SEQ ID NO：1的残基476至494或与SEQ ID NO：1具有至少70％序列同一性的SEQ ID NO：1的残基146至315或476至494的序列变体。 本发明的肽可用于治疗，预防或抑制受试者中疱疹病毒（例如，单纯疱疹病毒-1，人巨细胞病毒等）感染。
-
公开(公告)号：US20140045752A1
公开(公告)日：2014-02-13
申请号：US13985051
申请日：2012-02-16
申请人： David H. Coy , Linchun Sun
发明人： David H. Coy , Linchun Sun
摘要： Multicomponent compositions and methods of use thereof are disclosed herein. Some embodiments of the present invention include multicomponent compositions comprising a first component and a second component, where the first component comprises a notch influencing molecule and the second component comprises a GPCR targeted molecule. Kits comprising the multicomponent composition are also disclosed. Methods for providing the multicomponent composition to one or more cells are additionally provided. Further embodiments include methods of using the multicomponent composition such as, for example, methods of administering the multicomponent composition and method of treating organisms (such as mammals) using the multicomponent composition.
摘要翻译： 本文公开了多组分组合物及其使用方法。 本发明的一些实施方案包括包含第一组分和第二组分的多组分组合物，其中第一组分包含缺口影响分子，第二组分包含GPCR靶分子。 还公开了包含多组分组合物的试剂盒。 另外提供了将多组分组合物提供给一个或多个细胞的方法。 另外的实施方案包括使用多组分组合物的方法，例如使用多组分组合物施用多组分组合物的方法和治疗生物体（例如哺乳动物）的方法。
-
公开(公告)号：US20140045743A1
公开(公告)日：2014-02-13
申请号：US13962524
申请日：2013-08-08
IPC分类号： C07K14/005
CPC分类号： C07K14/005 , A61K38/00 , A61K38/04 , A61K38/162 , C07K7/00 , C07K7/06 , C07K7/08 , C12N7/00 , C12N2760/10022 , C12N2760/14122 , C12N2760/18422 , C12N2760/18433 , C12N2770/20022 , C12Q1/18 , G01N33/56988
摘要： The present invention provides compositions and methods for treating a coronavirus infection. A method embodiment comprises administering a polypeptide (preferably in a biocompatible pharmaceutical carrier) to a subject suffering from a coronavirus infection. The polypeptide comprises or consists of at least a portion of the fusion initiation region (FIR) of a coronavirus fusion protein. In some embodiments, the polypeptide comprises or consists of a sequence selected from SEQ ID NO: 2, 22, 23, 24, and 25 or an 8 to 40 contiguous amino acid residue portion thereof.
摘要翻译： 本发明提供了用于治疗冠状病毒感染的组合物和方法。 方法实施方案包括向患有冠状病毒感染的受试者施用多肽（优选在生物相容性药物载体中）。 多肽包含冠状病毒融合蛋白的融合起始区（FIR）的至少一部分或由其构成。 在一些实施方案中，多肽包含选自SEQ ID NO：2,22,23,24和25的序列或其8至40个连续氨基酸残基部分。
-
公开(公告)号：US20140017298A1
公开(公告)日：2014-01-16
申请号：US13841849
申请日：2013-03-15
发明人： Vijay JOHN , Srinivasa RAGHAVAN , Rubo ZHENG
IPC分类号： A61K9/127
CPC分类号： A61K9/1271
摘要： The disclosed invention involves creating coatings on liposomes to increase stability within the body for drug delivery. The present invention includes a composition used for drug delivery, comprising liposomes and hydrophobically modified polysaccharides with alkyl groups, wherein the alkyl groups physically attach to and coat the liposomes.
摘要翻译： 所公开的发明涉及在脂质体上产生涂层以提高体内用于药物递送的稳定性。 本发明包括用于药物递送的组合物，其包含脂质体和具有烷基的疏水改性的多糖，其中所述烷基物理附着并包被脂质体。
-
-
-
-
-
-
-
-
-
搜索结果
373 条记录 (耗时 0.032 秒)
